论文部分内容阅读
目的探讨依达拉奉联合尼莫地平治疗脑出血的临床疗效。方法选60例脑出血患者随机分为治疗组和对照组各30例,对照组以常规治疗,治疗组在常规治疗基础上加用依达拉奉针及尼莫地平针静脉滴注。观察两组治疗前后神经功能、颅内血肿大小、血浆ET-1水平变化,并进行比较。结果治疗组疗效总有效率73%,对照组总有效率40%。统计学处理,治疗组的疗效显著优于对照组(P<0.05)。同时,治疗组的神经功能恢复、血肿吸收、血浆ET-1降低均显著优于对照组(P<0.05)。结论依达拉奉联合尼莫地平能促进脑血肿吸收,具有明显的神经保护作用,对治疗早期脑出血安全可靠、疗效显著。
Objective To investigate the clinical efficacy of edaravone combined with nimodipine in the treatment of cerebral hemorrhage. Methods 60 patients with cerebral hemorrhage were randomly divided into treatment group and control group, 30 cases in each group. The control group was treated by conventional therapy. The treatment group was given intravenous infusion of edaravone and nimodipine on the basis of routine treatment. Before and after treatment, the neurological function, the size of intracranial hematoma and the plasma ET-1 level were observed and compared. Results The total effective rate of treatment group was 73%, control group, the total efficiency of 40%. Statistical analysis, the treatment group was significantly better than the control group (P <0.05). At the same time, the recovery of neurological function, the absorption of hematoma and the decrease of plasma ET-1 in the treatment group were significantly better than those in the control group (P <0.05). Conclusion Edaravone combined with nimodipine can promote the absorption of cerebral hematoma and has obvious neuroprotective effect. It is safe and reliable for the treatment of early cerebral hemorrhage and has significant curative effect.